Unknown PHASE4 INTERVENTIONAL 2-arm NCT01250340

Type 2 Diabetes Mellitus and Atherosclerosis

Type 2 Diabetes Mellitus: Role of Inflammation and Innate Immunity in The Pathogenesis of Endothelial Dysfunction and Atherosclerosis

Sponsor: University of Roma La Sapienza

Conditions Type 2 Diabetes Mellitus

Interventions Aspirin Placebo

Updated 5 times since 2017 Last updated: Nov 27, 2012 Started: Aug 31, 2010 Primary completion: Jan 31, 2011 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Type 2 Diabetes Mellitus and is currently ongoing. University of Roma La Sapienza leads this study, which shows 5 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

First recorded

Aug 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Roma La Sapienza
University of Rome Tor Vergata

Data source: University of Roma La Sapienza

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rome, Italy